4.2 The role of ANGPTL4 in mesenchymal metabolic shifts in diabetic kidney Defective metabolism, the gain of mesenchymal marker proteins in diverse kidney cell types, immune cell activation, proinflammatory cytokines, aberrant chemokine levels, and tubular cell apoptosis are key phenomena driving fibrosis in the diabetic kidney (Thomas et al., 2015
One of the most consequential changes in 2026 is the loss of exclusivity for semaglutide, beginning in early 2026 across major markets including India, China, Brazil, Turkey and Canada, with semaglutide having lost exclusivity in India on 20th March 2026
Patients included in the trial had HbA1c 7 to 10% and were treated with either: diet and exercise alone or 1 to 3 oral antidiabetic drugs (metformin, sulfonylurea, glitazone or sodium-glucose co-transporter 2 inhibitor)
T.Rowan-NashA